Loading clinical trials...
Loading clinical trials...
A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Conditions
Interventions
Carfilzomib
Dexamethasone
Locations
10
United States
City of Hope
Duarte, California, United States
Stanford Cancer Institute
Stanford, California, United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
Boston University Medical Center
Boston, Massachusetts, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Columbia University
New York, New York, United States
Start Date
February 1, 2013
Primary Completion Date
December 1, 2016
Completion Date
July 1, 2017
Last Updated
October 18, 2017
NCT06355934
NCT06427304
NCT07052903
NCT06383143
NCT06672237
NCT05758493
Lead Sponsor
Criterium, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions